Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 10 2025
0mins
Source: PRnewswire
Merger Announcement: NLS Pharmaceutics Ltd and Kadimastem Ltd have announced that the SEC has declared effective their registration statement related to their merger, which will create a new entity called NewCelX Ltd.
Significance of SEC Approval: The effectiveness of the SEC registration marks a significant milestone in the merger process, as stated by the CEOs of both companies.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
